ANGPT2 and neoplasm: BsAbs offer a means to surmount traditional limitations via T/NK-cell redirection, coordinated blockade of pro-tumor and immunosuppressive axes (e.g., VEGF/Ang-2; EGFRvIII×CD3), and remodeling of the tumor immune microenvironment (Table 3) 184.